Oxidative Medicine and Cellular Longevity

Oxidative Stress in Intervertebral Disc Degeneration and its Related Therapeutics 2022


Publishing date
01 May 2023
Status
Closed
Submission deadline
30 Dec 2022

Lead Editor

1Third Hospital of Hebei Medical University, Hebei, China

2Third Hospital of Hebei Medical University, Shijiazhuang, China

3The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

4Zhejiang University School of Medicine, Hangzhou, China

5University of New South Wales, Sydney, Australia

This issue is now closed for submissions.

Oxidative Stress in Intervertebral Disc Degeneration and its Related Therapeutics 2022

This issue is now closed for submissions.

Description

Intervertebral disc (IVD) degeneration, an important cause of discogenic lower back pain (LBP), has traditionally been thought to be an age-related process of the disc tissue caused by decreased proteoglycan content, eventually leading to decreased intervertebral height, endplate sclerosis and osteophyte formation. IVD degeneration can cause a variety of spinal diseases including lumbar disc herniation, lumbar spondylolisthesis, spinal stenosis, scoliosis, and cervical spondylopathy. Over the past decades, IVD degeneration-related diseases have been causing an enormous socio-economic burden and leading to low quality of life.

The process of IVD degeneration is complicated. Although the mechanism of IVD degeneration is not fully understood, altered mechanical loading, degradation of the extracellular matrix (ECM), increased secretion of inflammatory factors, excessive senescence, and aberrant apoptosis of IVD cells have proved to play important roles in the progression of IVD degeneration. Previous studies in humans and experimental animal models have well documented that oxidative stress and damage can result in excessive apoptosis and autophagy of IVD cells and further lead to IVD degeneration. However, the specific signalling pathways underlying the pathogenesis still remain elusive, making it very difficult to find potential therapeutics targeting that unclear mechanism.

This Special Issue aims to focus on four aspects:

1. The specific molecular pathways underlying oxidative stress-induced IVD degeneration and ageing.

2. Therapeutic molecules that attenuate the progression of IVD degeneration.

3. Biomaterials for IVD repair and regeneration.

4. Stem/ progenitor cells for IVD repair and regeneration.

Contributions with original research are extremely welcome if that would provide new insights for understanding the pathophysiological mechanism of oxidative damage-induced IVD degeneration and/or novel discovery of its diagnostics and therapeutics. Review articles that help better understand the existing knowledge regarding the role of oxidative stress and related therapeutics are also welcome. In particular, three-dimensional culture and hypoxic culture of IVD cells are greatly encouraged.

Potential topics include but are not limited to the following:

  • Oxidative stress in IVD degeneration and ageing related diseases, including LBP, lumbar disc herniation, lumbar spondylolisthesis, spinal stenosis, scoliosis, and cervical spondylopathy
  • Specific molecular pathways underlying oxidative stress-induced IVD degeneration and ageing
  • Potential therapeutic molecules to attenuate the progression of IVD degeneration
  • Novel or potential diagnostics and prognosis for IVD degeneration- related diseases
  • Original research on potential medicinal plants are also welcome if the mechanism or molecular targets are also elucidated in treating IVD degeneration-related diseases
  • Bioinformatical analysis of the underlying mechanisms related to oxidative stress-induced IVD degenerative diseases, including but not limited to differential gene expression, functional and pathway enrichment analyses, and module analyses for protein-protein interaction (PPI) network
  • Bioengineering therapeutics for oxidative damage-induced IVD degenerative diseases, including biomaterials and stem/progenitor cells
  • IVD degeneration models induced by oxidative damage, including in vivo, ex vivo, and in vitro models
  • Meta-analysis of randomized controlled trials or primary clinical data used to evaluate the efficacy, or otherwise, of novel or potential therapeutics for IVD degeneration-related diseases

Articles

  • Special Issue
  • - Volume 2023
  • - Article ID 9020236
  • - Research Article

Establishment of Ferroptosis-Related Key Gene Signature and Its Validation in Compression-Induced Intervertebral Disc Degeneration Rats

Jiangbo Guo | Yilin Yang | ... | Huilin Yang
  • Special Issue
  • - Volume 2022
  • - Article ID 1372483
  • - Research Article

Integrative Bioinformatics Analysis Revealed Mitochondrial Dysfunction-Related Genes Underlying Intervertebral Disc Degeneration

Zhengya Zhu | Zhongyuan He | ... | Shaoyu Liu
  • Special Issue
  • - Volume 2022
  • - Article ID 3511967
  • - Research Article

miR-328-5p Induces Human Intervertebral Disc Degeneration by Targeting WWP2

Jing Yan | Lun-Gang Wu | ... | Quan Zhou
  • Special Issue
  • - Volume 2022
  • - Article ID 2481071
  • - Research Article

Development of a Novel Inflammatory-Associated Gene Signature and Immune Infiltration Patterns in Intervertebral Disc Degeneration

Tao Lan | Zhihao Hu | ... | Yuantao Zhang
  • Special Issue
  • - Volume 2022
  • - Article ID 7548145
  • - Research Article

Specific PFKFB3 Inhibitor Memorably Ameliorates Intervertebral Disc Degeneration via Inhibiting NF-κB and MAPK Signaling Pathway and Reprogramming of Energy Metabolism of Nucleus Pulposus Cells

Xiankun Cao | Xin Wang | ... | Jie Zhao
  • Special Issue
  • - Volume 2022
  • - Article ID 9684062
  • - Research Article

Irisin Ameliorates Intervertebral Disc Degeneration by Activating LATS/YAP/CTGF Signaling

Taiqiu Chen | Youxi Lin | ... | Dongsheng Huang
Oxidative Medicine and Cellular Longevity
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision133 days
Acceptance to publication34 days
CiteScore10.100
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.